Search

Author/Creator Ros, Willeke

2. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies. Issue 8 (2nd May 2020)

Authors:
Piha‐Paul, Sarina A.; Oh, Do‐Youn; Ueno, Makoto; Malka, David; Chung, Hyun Cheol; Nagrial, Adnan; Kelley, Robin K.; Ros, Willeke; Italiano, Antoine; Nakagawa, Kazuhiko; Rugo, Hope S.; de Braud, Filippo; Varga, Andrea Iolanda; Hansen, Aaron; Wang, Hui; Krishnan, Suba; Norwood, Kevin G.; Doi, Toshi...
Journal:
International journal of cancer
Issue:
Volume 147:Issue 8(2020)
Page Start:
2190
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). Issue 3 (16th March 2023)

Authors:
Postel-Vinay, Sophie; Lam, Vincent K; Ros, Willeke; Bauer, Todd M; Hansen, Aaron R; Cho, Daniel C; Stephen Hodi, F; Schellens, Jan H M; Litton, Jennifer K; Aspeslagh, Sandrine; Autio, Karen A; Opdam, Frans L; McKean, Meredith; Somaiah, Neeta; Champiat, Stephane; Altan, Mehmet; Spreafico, Anna; Ra...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 11:Issue 3(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Issue 10 (27th October 2022)

Authors:
Hamid, Omid; Chiappori, Alberto A; Thompson, John A; Doi, Toshihiko; Hu-Lieskovan, Siwen; Eskens, Ferry A L M; Ros, Willeke; Diab, Adi; Spano, Jean-Philippe; Rizvi, Naiyer A; Wasser, Jeffrey S; Angevin, Eric; Ott, Patrick A; Forgie, Alison; Yang, Wenjing; Guo, Cen; Chou, Jeffrey; El-Khoueiry, Ant...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 10(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort. (15th April 2020)

Authors:
Chiappori, Alberto; Thompson, John; Eskens, Fredericus; Spano, Jean-Philippe; Doi, Toshihiko; Hamid, Omid; Diab, Adi; Rizvi, Naiyer; Hu-Lieskovan, Siwen; Ros, Willeke; Thomas, Jacob; Forgie, Alison; Yang, Wenjing; Liao, Ken; Li, Ray; Kazazi, Farhad; Chou, Jeffrey; khoueiry, Anthony El
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 1
Page Start:
A9
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗